Last reviewed · How we verify
Co-Trimoxazole; TMP-SMZ
At a glance
| Generic name | Co-Trimoxazole; TMP-SMZ |
|---|---|
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Sulfamethoxazole Prophylaxis Duration After Renal Transplantation (NA)
- Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy (PHASE4)
- Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve. (PHASE3)
- Caspofungin for Pneumocystis Pneumonia in PLWHIV.
- Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy (NA)
- Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease (PHASE4)
- Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-Trimoxazole; TMP-SMZ CI brief — competitive landscape report
- Co-Trimoxazole; TMP-SMZ updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI